Skip to content

Clinical Outcomes From Nalmefene

Clinical Outcomes From Injectable Nalmefene in the Emergency Department (COINED)

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05808881
Acronym
COINED
Enrollment
0
Registered
2023-04-12
Start date
2023-06-30
Completion date
2024-05-31
Last updated
2023-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Overdose

Brief summary

The purpose of this study is to assess the effectiveness of nalmefene relative to naloxone for the reversal of opioid intoxication in emergency department (ED) settings.

Interventions

for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration

DRUGNaloxone Hydrochloride Injection

for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration

Sponsors

Purdue Pharma LP
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Presumed or known opioid overdose in community settings. 2. Experiencing clinically significant respiratory depression based on appropriate medical judgement. 3. Patient airway is open and unobstructed at the time of enrollment. (Utilization of oral pharyngeal or nasal pharyngeal airway is allowed.) 4. Pre-hospital naloxone administration is allowed.

Exclusion criteria

1. Patient age known or estimated to be less than 18 years. 2. Patient has one or more additional documented acute medical, traumatic, toxicologic, or psychiatric conditions that would extend length of treatment or adversely alter the clinical outcome. 3. Cardiac arrest, secondary to opioid intoxication. 4. Arrested, jailed, or imprisoned patients. 5. Inappropriate for the study per judgement of research team.

Design outcomes

Primary

MeasureTime frameDescription
Reversal of Respiratory DepressionUp to 3 hoursNormalization of the end tidal carbon dioxide value (if measured) to between 35 and 45 mmHg and/or ≥5 breaths per minute increase in respiratory rate from baseline (pre-dose) measurement, with rate of at least 12 breaths per minute.

Secondary

MeasureTime frameDescription
Time to Reversal from administration of opioid antagonistUp to 3 hours
Recurrence of Respiratory DepressionUp to 3 hoursIncreased end tidal carbon dioxide value (if measured) above 45 mmHg when previously within the normal range and/or ≥5 breaths per minute decrease in respiratory rate from maximum post-reversal measurement, with a rate of at most 12 breaths per minute.
ED DispositionUp to 3 hoursOne of the following will apply: * ED Discharge * Hospital Admission * ICU Admission * Left against medical advice * Transfer to another facility * Death.
Drug DosingUp to 3 hours1. Dose administered for each opioid antagonist given to patients during their ED encounter - * Individual dose amount and frequency * Cumulative dose 2. Any pre-hospital naloxone given prior to ED arrival - * Dose amount, route
Richmond-Agitation Sedation Scale (RASS) ScoreUp to 3 hoursThis is a single-item instrument used to quickly assess the degree of patient alertness and agitation in emergency and critical care settings. It is an observational assessment conducted by healthcare providers, and it can be completed in seconds. The scale uses integers from -5 to +4, each with its own clear anchor. A score of 0 means that the patient is alert and calm. Negative integers indicate diminished responsiveness and consciousness, with -1 indicating that a patient will open their eyes or make eye contact for 10 or more seconds when awakened by voice, and -5 meaning that the patient is unarousable by voice or physical stimulation. Positive integers indicate an increased level of arousal or agitation. The positive end of the scale spans from +1 (anxious, apprehensive, but not aggressive) to +4 (combative, violent, danger to staff).
Clinical Opioid Withdrawal Scale (COWS) ScoreUp to 3 hoursThis is an observational assessment performed by a clinician to diagnose and assess the severity of opioid withdrawal symptoms. Eleven different opioid withdrawal symptoms are included in the COWS. The clinician will score the presence and severity of each symptom, with 0 indicating that the symptom is absent and more severe symptoms warranting a higher score. Individual symptom scores are then added to determine the overall severity of the patient's withdrawal. Total scores range from 5 to 48 where 5 - 12 = mild; 13 - 24 = moderate; 25 - 36 moderately severe; and greater than 36 = severe withdrawal.
Oxygen saturation levelUp to 3 hoursPulse oximetry monitoring will be used to assess the patient's oxygen saturation level (SpO2), expressed as a percentage from 0 to 100.
Length of time during ED encounterUp to 3 hoursDefined as the difference between time at Triage to time at ED Disposition

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026